Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depression Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 and Digoxin in Healthy Subjects

NCT01266590
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Slow-wave Sleep Deprivation in Depression

NCT01189591
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Slow-wave deprivation
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 14, 2026, 9:16 AM EDT
Recruiting No phase listed Observational

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

NCT07528014
View directory record Official record
Conditions
Depressed Mood
Interventions
Not listed
Lead sponsor
Salma Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
La Jolla, California • Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

NCT00036335
View directory record Official record
Conditions
Depression, Pain
Interventions
Duloxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
25
States / cities
Peoria, Arizona • Burbank, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 14, 2026, 9:16 AM EDT
Not yet recruiting Phase 1 Interventional

Ketamine Biomarker Validation

NCT07307768
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
Drug
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 14, 2026, 9:16 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression

NCT05933148
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Siemens 7T MRI, Sham Neurofeedback
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)

NCT01724112
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2940094, Placebo
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
North Miami, Florida • Oakland Park, Florida • University Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

NCT02498392
View directory record Official record
Conditions
Depressive Disorder, Anxiety
Interventions
JNJ-42165279, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Costa Mesa, California • Oceanside, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Improving Therapeutic Learning in Depression: Proof of Concept

NCT02376257
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
250 mg DCS, 100 mg Modafinil, Placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

NCT03559192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-67953964, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 14, 2026, 9:16 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

NCT05894902
View directory record Official record
Conditions
Major Depression, Post Traumatic Stress Disorder
Interventions
SM-001
Drug
Lead sponsor
Advanced Integrative Medical Science Institute
Other
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT01110902
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 14, 2026, 9:16 AM EDT
Completed No phase listed Observational

A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse

NCT02476877
View directory record Official record
Conditions
Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder, Major Depression
Interventions
Not listed
Lead sponsor
Advanced Clinical Laboratory Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 14, 2026, 9:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder

NCT04874077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study of Ibuprofen Effects on Brain Function

NCT02507219
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ibuprofen
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 14, 2026, 9:16 AM EDT
Not listed No phase listed Observational

Machine Learning to Predict Clinical Response to TMS

NCT03847688
View directory record Official record
Conditions
Depression, Unipolar
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NCT02218008
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Colton, California • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 14, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

NCT06136546
View directory record Official record
Conditions
Depressive Disorder, Major, Inflammation
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 14, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

NCT07217223
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Interventions
Spaced Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 14, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 14, 2026, 9:16 AM EDT
Recruiting Phase 3 Interventional

Biomarker-guided rTMS for Treatment Resistant Depression

NCT04041479
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
22 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 14, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional

One-Day cTBS Over the Precuneus

NCT07758010
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
Interventions
Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 14, 2026, 9:16 AM EDT